{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:51:44Z","timestamp":1792299104088,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ymgme.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T03:49:26Z","timestamp":1538020166000},"page":"224-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease \u2013 A systematic literature review by a European panel of experts"],"prefix":"10.1016","volume":"126","author":[{"given":"Dominique P.","family":"Germain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Falissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3355","authenticated-orcid":false,"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.09.007_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0015","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0030","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s004390050292","article-title":"Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease","volume":"98","author":"Germain","year":"1996","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<420::AID-AJMG6>3.0.CO;2-Z","article-title":"Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG)","volume":"84","author":"Ashton-Prolla","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0050","article-title":"Enzyme replacement therapy in Fabry disease \u2013 methodology of a systematic literature review by a European panel of experts","author":"Elliot","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0055","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Germain","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0060","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","author":"Spada","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"Expert consensus statement on therapeutic goals in Fabry disease","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study","volume":"26","author":"Baehner","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2003.tb00220.x","article-title":"Head-impulse testing in Fabry disease--vestibular function in male and female patients","volume":"92","author":"Palla","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0085","first-page":"7","article-title":"Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment na\u00efve or formerly treated with agalsidase beta or agalsidase alfa","volume":"23","author":"Goker-Alpan","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0090","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S80928","article-title":"Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease","volume":"9","author":"Gol\u00e1\u0148","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0100","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00415-007-0575-y","article-title":"Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy","volume":"254","author":"Palla","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0105","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Fabry Outcome Survey European investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy \u2013 a retrospective analysis from the Fabry outcome survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2215\/CJN.03130411","article-title":"The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy","volume":"7","author":"Feriozzi","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0125","first-page":"87","article-title":"Interdisciplinary study group on Fabry disease. Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy","volume":"30","author":"Sergi","year":"2010","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0135","first-page":"21","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00228-007-0460-8","article-title":"Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance","volume":"64","author":"Mougenot","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ymgme.2012.05.011","article-title":"Enzyme replacement therapy improves cardiac features and severity of Fabry disease","volume":"107","author":"Motwani","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0165","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","article-title":"Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation","volume":"27","author":"Warnock","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0170","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0175","first-page":"406","article-title":"Safe and successful treatment with agalsidase beta during pregnancy in Fabry disease","volume":"9","author":"Senocak Tasci","year":"2015","journal-title":"Iran. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0180","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM200303203481224","article-title":"PR interval and the response to enzyme-replacement therapy for Fabry's disease","volume":"348","author":"Waldek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0185","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/147323000703500418","article-title":"Enzyme replacement therapy in patients with Fabry's disease","volume":"35","author":"Tsuboi","year":"2007","journal-title":"J. Int. Med. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2018.09.007_bb0190","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1007\/s10545-008-0930-x","article-title":"Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage","volume":"31","author":"Wang","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrneph.2009.71","article-title":"Unusual renal presentation of Fabry disease in a female patient","volume":"5","author":"Abaterusso","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1620\/tjem.217.169","article-title":"Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease","volume":"217","author":"Masugata","year":"2009","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0205","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.placenta.2010.02.004","article-title":"Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy","volume":"31","author":"Bouwman","year":"2010","journal-title":"Placenta"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0210","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1447-0756.2009.01164.x","article-title":"Treatment with agalsidase beta during pregnancy in Fabry disease","volume":"36","author":"Politei","year":"2010","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0215","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.humpath.2011.07.020","article-title":"Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature","volume":"43","author":"Thurberg","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0220","first-page":"23","article-title":"Therapeutic impact of cardiac rehabilitation exercise on cardiac Fabry woman treated with enzyme replacement therapy","volume":"13","author":"Kitai","year":"2016","journal-title":"Cardiol. Metab. Endo."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0225","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1536\/ihj.15-475","article-title":"Novel \u03b1-galactosidase a mutation [K391E] in a young woman with severe cardiac and renal manifestations of Fabry disease","volume":"57","author":"Wakakuri","year":"2016","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ymgme.2015.11.014","article-title":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","volume":"117","author":"Arends","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00392-009-0084-3","article-title":"Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy","volume":"99","author":"Prinz","year":"2010","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejmg.2009.12.004","article-title":"Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: a case report","volume":"53","author":"Germain","year":"2010","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0255","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","article-title":"Clinical observation of patients with Fabry disease after switching from agalsidase beta [Fabrazyme] to agalsidase alfa [Replagal]","volume":"14","author":"Tsuboi","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0260","first-page":"105","article-title":"Successful management of enzyme replacement therapy in related Fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme (\u00ae)) to agalsidase alfa (replagal (\u00ae))","volume":"15","author":"Tsuboi","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0265","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cge.12590","article-title":"Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations -- different outcome?","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0270","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1529-8027.2011.00365.x","article-title":"Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy","volume":"16","author":"\u00dc\u00e7eyler","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0280","first-page":"33","article-title":"Effect of reduced agalsidase beta dosage in Fabry patients: the Australian experience","volume":"3","author":"Ghali","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ckj\/sfs114","article-title":"Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease","volume":"5","author":"Fujii","year":"2012","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0290","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0300","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary [lyso]Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0305","doi-asserted-by":"crossref","first-page":"282487","DOI":"10.1155\/2013\/282487","article-title":"Long-term effect of enzyme replacement therapy with Fabry disease","volume":"2013","author":"Komori","year":"2013","journal-title":"Int. J. Otolaryngol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003146","article-title":"Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation [IVS4+919G>A]","volume":"3","author":"Lin","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0315","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","article-title":"Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine [lyso-Gb3] might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation [IVS4+919G>A]","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0325","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/gft452","article-title":"Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease","volume":"29","author":"Prabakaran","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0330","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry disease initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0335","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10545-014-9783-7","article-title":"Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy","volume":"38","author":"Suntjens","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0340","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/heartjnl-2015-308897","article-title":"The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy","volume":"102","author":"Schmied","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0345","doi-asserted-by":"crossref","first-page":"e0143940","DOI":"10.1371\/journal.pone.0143940","article-title":"Positron emission tomography and magnetic resonance imaging of the brain in Fabry disease: a nationwide, long-time, prospective follow-up","volume":"10","author":"Korsholm","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5414\/CN108317","article-title":"A heterozygous female with Fabry disease due to a novel \u03b1-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes","volume":"83","author":"Takahashi","year":"2015","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0355","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinbiochem.2014.09.018","article-title":"A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene","volume":"48","author":"Tuttolomondo","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gene.2013.11.063","article-title":"Lysosome-associated protein 1 [LAMP-1] and lysosome-associated protein 2 [LAMP-2] in a larger family carrier of Fabry disease","volume":"536","author":"Pereira","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0365","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1210\/jc.2006-0858","article-title":"Endocrine dysfunction in patients with Fabry disease","volume":"91","author":"Faggiano","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0370","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/gim.2014.28","article-title":"Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1","volume":"16","author":"Tsuboi","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0375","first-page":"12","article-title":"Management of neuropathic pain in Fabry disease","volume":"33","author":"Turker","year":"2016","journal-title":"J. Neurol. Sci. Turk."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0380","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2377-10-38","article-title":"Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests","volume":"10","author":"Biegstraaten","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0385","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1161\/HYPERTENSIONAHA.112.195685","article-title":"Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine","volume":"60","author":"Rombach","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0390","doi-asserted-by":"crossref","first-page":"gfw334","DOI":"10.1093\/ndt\/gfw334","article-title":"Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease","author":"Lenders","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0395","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0400","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0405","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0410","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","article-title":"A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant","volume":"136","author":"Germain","year":"2001","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0415","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ymgme.2018.09.007_bb0420","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","article-title":"Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry","volume":"119","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0430","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0435","first-page":"45","article-title":"Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry Registry","volume":"38","author":"Wilcox","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0440","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2018.09.007_bb0445","series-title":"Principles of Human Genetics and Mendelian Inheritance, in Neurometabolic Hereditary Disease of Adults","author":"Germain","year":"2018"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218301926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:22:39Z","timestamp":1761088959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218301926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1096719218301926"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.09.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease \u2013 A systematic literature review by a European panel of experts","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}